THE COST-EFFECTIVENESS OF DELAYED RELEASE DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE MEXICAN SOCIAL SECURITY INSTITUTE (IMSS)
Author(s)
de Anda JA1, Noda C1, Anaya P1, Azamar A2, Machado M3, Serafini P3
1IMS Health, Mexico City, Mexico, 2Stendhal, Mexico City, Mexico, 3Biogen, Sao Paulo, Brazil
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PND40
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now